

# Have you been diagnosed with Pulmonary Arterial Hypertension (PAH)?

NIH...Turning Discovery Into Health®



Researchers at the National Institutes of Health (NIH) Clinical Center are testing if spironolactone can be used to treat pulmonary arterial hypertension (PAH). Spironolactone is a medication that can help with fluid retention, however it may also be beneficial in PAH by controlling inflammation and improving blood vessel function in the lungs.

*If you have been diagnosed with PAH talk to your doctor about joining this study.*

## Participation includes:

- A medical history, physical examination, blood tests, lung function tests, exercise tests, imaging scans and quality of life questionnaires.
- 2 to 3 visits to the NIH Clinical Center over a 6-month period.
- You will be assigned to take spironolactone or placebo (inactive pill) for 24 weeks. Neither you nor the study team will know if you are receiving the medication or placebo.

## You may be eligible if you are:

- At least 18 years old and diagnosed with PAH.
- Not pregnant or breastfeeding.

All study-related tests and medication are provided at no cost. Travel within the U.S. and accommodations may be reimbursed by the study.

The NIH Clinical Center, America's Research Hospital is located in Bethesda, Maryland in the Washington, DC metro area.

Scan QR code for more information!



National Institutes of Health  
Clinical Center

**For more information:**  
**NIH Clinical Center Office of Patient Recruitment**  
**1-800-411-1222**  
**PRPL@cc.nih.gov**  
**TTY for the deaf or hard of hearing: 1-866-411-1010**  
**Online: <https://go.usa.gov/xR7ma>**  
**Refer to NIH Study 12-CC-0211**

